fludarabine and rhenium

fludarabine has been researched along with rhenium in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Blumstein, N; Buchmann, I; Buck, AK; Bunjes, D; Döhner, H; Glatting, G; Kotzerke, J; Neumaier, B; Reske, SN; Ringhoffer, M; Schauwecker, P; Stilgenbauer, S; von Harsdorf, S; Wiesneth, M; Zenz, T1
Bornhäuser, M; Ehninger, G; Kotzerke, J; Schetelig, J; Schneider, S; Strumpf, A; Wunderlich, G1

Trials

2 trial(s) available for fludarabine and rhenium

ArticleYear
188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.
    British journal of haematology, 2005, Volume: 130, Issue:4

    Topics: Aged; Antibodies, Monoclonal; Antigens, CD; Antigens, Differentiation; Antilymphocyte Serum; Antineoplastic Agents; Cell Adhesion Molecules; Female; Follow-Up Studies; Hematologic Diseases; Humans; Immunosuppressive Agents; Leukemia; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Radioimmunotherapy; Radioisotopes; Radiometry; Rhenium; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Yttrium Radioisotopes

2005
Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:10

    Topics: Aged; Alemtuzumab; Allografts; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Adhesion Molecules; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Feasibility Studies; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Immunoconjugates; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Prospective Studies; Radioimmunotherapy; Radioisotopes; Rhenium; T-Lymphocytes; Transplantation Conditioning; Vidarabine

2015